Allergan agrees to acquire AqueSys for $300 million
Life Sciences
Business Deals
(MarketWatch) – Allergan PLC said late Thursday it agreed to acquire privately-held AqueSys Inc. for $300 million cash. AqueSys makes medical devices that are placed in the eye to reduce pressure associated with glaucoma. Allergan said that it will also pay milestone payments for regulatory approval and commercialization of AqueSys’s XEN45 device, which is expected to get U.S. approval in late 2016 or early 2017. Allergan plans to close the acquisition in the fourth quarter.
Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.
The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.
Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.